Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Cash (2016 - 2026)

Gyre Therapeutics has reported Change in Cash over the past 16 years, most recently at -$3.3 million for Q4 2025.

  • Quarterly Change in Cash rose 17.79% to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, up 216.41% year-over-year, with the annual reading at $25.3 million for FY2025, 216.41% up from the prior year.
  • Change in Cash was -$3.3 million for Q4 2025 at Gyre Therapeutics, down from $3.9 million in the prior quarter.
  • Over five years, Change in Cash peaked at $52.7 million in Q1 2021 and troughed at -$52.3 million in Q3 2022.
  • The 5-year median for Change in Cash is -$1.8 million (2024), against an average of $1.0 million.
  • Year-over-year, Change in Cash crashed 372.39% in 2021 and then skyrocketed 1793.07% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$14.8 million in 2021, then soared by 209.58% to $16.2 million in 2022, then plummeted by 54.22% to $7.4 million in 2023, then crashed by 154.55% to -$4.1 million in 2024, then increased by 17.79% to -$3.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Cash are -$3.3 million (Q4 2025), $3.9 million (Q3 2025), and $21.4 million (Q2 2025).